Assist-Devices bei terminaler Herzinsuffizienz

Die terminale Herzinsuffizienz stellt eine der Haupttodesursachen in Deutschland dar. Als einzige kurative Therapieoption ist die Herztransplantation weiterhin der Goldstandard. Jedoch übertrifft die Anzahl der Patienten mit terminaler Herzinsuffizienz die Zahl der jährlich durchgeführten Transplantationen um ein Vielfaches. Herzunterstützungssysteme haben eine wachsende Bedeutung als Alternative oder Überbrückung zur Transplantation erlangt.

Schlüsselwörter

Herzunterstützungssysteme - LVAD - Herzinsuffizienz

• Literatur

• 1 Lund LH, Khush KK, Cherikh WS. et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant 2017; 36: 1037-1046 doi:10.1016/j.healun.2017.07.019
• 2 Rojas SV, Haverich A. [Heart failure: ventricular assist devices and cardiac transplantation: A review of current surgical innovations]. Chirurg 2019; 90: 110-116 doi:10.1007/s00104-018-0774-3
• 3 Gomez-Soto FM, Andrey JL, Garcia-Egido AA. et al. Incidence and mortality of heart failure: A community-based study. Int J Cardiol 2011; 151: 40-45 doi:10.1016/j.ijcard.2010.04.055
• 4 Gummert JF, Haverich A, Schmitto JD. et al. Permanent Implantable Cardiac Support Systems. Dtsch Arztebl Int 2019; 116: 843-848 doi:10.3238/arztebl.2019.0843
• 5 Kirklin JK, Naftel DC, Pagani FD. et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 2015; 34: 1495-1504 doi:10.1016/j.healun.2015.10.003
• 6 Potapov EV, Antonides C, Crespo-Leiro MG. et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg 2019; 56: 230-270 doi:10.1093/ejcts/ezz098
• 7 Rojas SV, Hanke JS, Haverich A. et al. Chronic ventricular assist device support: surgical innovation. Curr Opin Cardiol 2016; 31: 308-312 doi:10.1097/HCO.0000000000000290
• 8 Schramm R, Morshuis M, Schoenbrodt M. et al. Current perspectives on mechanical circulatory support. Eur J Cardiothorac Surg 2019; 55: i31-i37 doi:10.1093/ejcts/ezy444
• 9 Fang JC. Rise of the machines – left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med 2009; 361: 2282-2285 doi:10.1056/NEJMe0910394
• 10 Rojas SV, Hanke JS, Avsar M. et al. Left Ventricular Assist Device Therapy for Destination Therapy: Is Less Invasive Surgery a Safe Alternative?. Rev Esp Cardiol (Engl Ed) 2018; 71: 13-17 doi:10.1016/j.rec.2017.03.023
• 11 Pya Y, Malý J, Bekbossynova M. et al. First human use of a wireless coplanar energy transfer coupled with a continuous-flow left ventricular assist device. J Heart Lung Transplant 2019; 38: 339-343 doi:10.1016/j.healun.2019.01.1316
• 12 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975 doi:10.1002/ejhf.592
• 13 Mehra MR, Goldstein DJ, Uriel N. et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med 2018; 378: 1386-1395 doi:10.1056/NEJMoa1800866
• 14 de By TMMH, Mohacsi P, Gahl B. et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. Eur J Cardiothorac Surg 2018; 53: 309-316 doi:10.1093/ejcts/ezx320
• 15 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128 doi:10.1056/NEJMoa1504720
• 16 Rogers JG, Pagani FD, Tatooles AJ. et al. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. N Engl J Med 2017; 376: 451-460 doi:10.1056/NEJMoa1602954
• 17 Dandel M, Potapov E, Krabatsch T. et al. Load dependency of right ventricular performance is a major factor to be considered in decision making before ventricular assist device implantation. Circulation 2013; 128: S14-S23 doi:10.1161/CIRCULATIONAHA.112.000335
• 18 Rosenkranz S, Gibbs JSR, Wachter R. et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016; 37: 942-954 doi:10.1093/eurheartj/ehv512
• 19 Mehra MR, Uriel N, Naka Y. et al. A Fully Magnetically Levitated Left Ventricular Assist Device – Final Report. N Engl J Med 2019; 380: 1618-1627 doi:10.1056/NEJMoa1900486
• 20 Schramm R, Zittermann A, Morshuis M. et al. Comparing short-term outcome after implantation of the HeartWare^® HVAD^® and the Abbott^® HeartMate 3 ^® . ESC Heart Fail 2020; 7: 908-914 doi:10.1002/ehf2.12649
• 21 Kirklin JK, Pagani FD, Kormos RL. et al. Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. J Heart Lung Transplant 2017; 36: 1080-1086 doi:10.1016/j.healun.2017.07.005